Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 10, Issue 3, Pages 224-231Publisher
SPRINGER
DOI: 10.1007/s11910-010-0105-7
Keywords
Low-grade glioma; Astrocytoma; Oligodendroglioma; Oligoastrocytoma; Mixed glioma; IDH; Molecular cytogenetics; Chemotherapy; Temozolomide; Radiation therapy
Categories
Ask authors/readers for more resources
The optimal management of patients with low-grade glioma (LGG) is controversial. The controversy largely stems from the lack of well-designed clinical trials with adequate follow-up to account for the relatively long progression-free survival and overall survival of patients with LGG. Nonetheless, the literature increasingly suggests that expectant management is no longer optimal. Rather, there is mounting evidence supporting active management including consideration of surgical resection, radiotherapy, chemotherapy, molecular and histopathologic characterization, and use of modern imaging techniques for monitoring and prognostication. In particular, there is growing evidence favoring extensive surgical resection and increasing interest in the role of chemotherapy (especially temozolomide) in the management of these tumors. In this review, we critically analyze emerging trends in the literature with respect to management of LGG, with particular emphasis on reports published during the past year.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available